New research presented at the European Congress on Obesity in Istanbul, Turkey (May 12–15) shows the use of the new GLP-1 ...
Pulmatrix, Inc. ("Pulmatrix" or the "Company") , a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and ...
Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results